Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06227221 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 2025 to Oct 2028 Start date: Feb 2025 to Feb 2026 · Completion date: Jun 2028 to Jun 2029v3 Show 2 more changesShow less
    • Start date: Feb 2025 to Feb 2026
    • Completion date: Jun 2028 to Jun 2029
  2. Enrollment target: 60 to 10 Start date: Jun 2024 to Feb 2025 · Primary completion date: Jan 2026 to Oct 2025 · Completion date: Dec 2026 to Jun 2028 · 2 morev2 Show 5 more changesShow less
    • Start date: Jun 2024 to Feb 2025
    • Primary completion date: Jan 2026 to Oct 2025
    • Completion date: Dec 2026 to Jun 2028
    • Secondary endpoints: details revised at 5 of 5 entries
    • Study title shortened, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.
Trial Details
NCT Number NCT06227221
Lead Sponsor Second Xiangya Hospital of Central South University
Conditions Type 1 Diabetes
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov